» Articles » PMID: 27495238

Recombinant Production of Medium- to Large-sized Peptides in Escherichia Coli Using a Cleavable Self-aggregating Tag

Overview
Publisher Biomed Central
Date 2016 Aug 7
PMID 27495238
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Peptides have recently become attractive for therapeutic applications. However, efficient production of medium- to large-sized peptides (30-100 amino acids [aa]) remains challenging both by recombinant and chemical synthesis. We previously reported the formation of active enzyme aggregates in Escherichia coli cells induced by the short β-structured peptide ELK16 (LELELKLKLELELKLK) and developed a streamlined protein expression and purification approach. In this approach, a cleavable self-aggregating tag (cSAT) consisting of an intein molecule and ELK16 was used to release the recombinant peptides with reasonable purity from active aggregates.

Results: In this work, we extended the cSAT approach to a generalized expression and purification solution for a set of medium- to large-sized peptides with important therapeutic uses, including human glucagon-like peptide 1 (31 aa), B-type natriuretic peptide (32 aa), exendin 4 (39 aa), chemokine (C-C motif) ligand 5 (also known as RANTES, 66 aa), stromal cell-derived factor 1α (67 aa), insulin-like growth factor 1 (70 aa), and leptin (146 aa). After intein-mediated cleavage, the soluble peptides were released directly into the supernatant while insoluble peptides could be refolded and purified by reverse phase high-performance liquid chromatography. Additionally, an N-terminal thioredoxin tag was added upstream of the target peptides, which can be removed by enterokinase cleavage, generating native N-terminus for target peptides. Final yields of the peptides ranged from 0.1 to 1.8 μg/mg wet cell weight at laboratory scale.

Conclusions: The approach described in this study provides a fast and efficient route to express and purify peptides that are difficult or expensive to produce by chemical synthesis or by ordinary recombinant methods. It is particularly well suited for large peptides, peptides likely to be degraded, and peptides that have toxic effects on the host. It can greatly reduce the cost and time of downstream processing, and thus may be useful for both industrial manufacture and laboratory applications.

Citing Articles

A miniature low-immunogenic platform for the biosynthesis of self-assembling protein nanoparticles.

Polinova A, Serkina A, Volkova M, Gorbunov A, Sannikova E, Gubaidullin I Nanotheranostics. 2025; 9(1):67-81.

PMID: 40078315 PMC: 11898719. DOI: 10.7150/ntno.98946.


Conditional Split Inteins: Adaptable Tools for Programming Protein Functions.

Shepherd C, Lawson-Williams M, Holland A, Bello A, Sexton D, Olorunniji F Int J Mol Sci. 2025; 26(2).

PMID: 39859302 PMC: 11766414. DOI: 10.3390/ijms26020586.


Unveiling the Pain Relief Potential: Harnessing Analgesic Peptides from Animal Venoms.

Pereira A, Cavalcante J, Angstmam D, Almeida C, Soares G, Pucca M Pharmaceutics. 2023; 15(12).

PMID: 38140106 PMC: 10748172. DOI: 10.3390/pharmaceutics15122766.


A novel protein purification scheme based on salt inducible self-assembling peptides.

Zeng G, Zheng Y, Xiang Y, Liu R, Yang X, Lin Z Microb Cell Fact. 2023; 22(1):224.

PMID: 37899435 PMC: 10614350. DOI: 10.1186/s12934-023-02229-5.


Expression, Purification and Characterization of Functional Teduglutide Using GST Fusion System in Prokaryotic Cells.

Alizadeh A, Rasouli S, Jamshidi Kandjani O, Hemmati S, Dastmalchi S Adv Pharm Bull. 2023; 13(3):592-600.

PMID: 37646058 PMC: 10460804. DOI: 10.34172/apb.2023.064.


References
1.
Jeong K, Lee S . High-level production of human leptin by fed-batch cultivation of recombinant Escherichia coli and its purification. Appl Environ Microbiol. 1999; 65(7):3027-32. PMC: 91452. DOI: 10.1128/AEM.65.7.3027-3032.1999. View

2.
Appay V, Rowland-Jones S . RANTES: a versatile and controversial chemokine. Trends Immunol. 2001; 22(2):83-7. DOI: 10.1016/s1471-4906(00)01812-3. View

3.
Bray B . Large-scale manufacture of peptide therapeutics by chemical synthesis. Nat Rev Drug Discov. 2003; 2(7):587-93. DOI: 10.1038/nrd1133. View

4.
Kolterman O, Buse J, Fineman M, Gaines E, Heintz S, Bicsak T . Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2003; 88(7):3082-9. DOI: 10.1210/jc.2002-021545. View

5.
Zhang Z, Yang S, Dou H, Mao J, Li K . Expression, purification, and C-terminal amidation of recombinant human glucagon-like peptide-1. Protein Expr Purif. 2004; 36(2):292-9. DOI: 10.1016/j.pep.2004.03.014. View